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Abstract
Background: Mammographic density is a strong predictor of breast cancer risk and is increased
by hormone replacement therapy (HRT). Some associations with genetic polymorphisms in
enzymes involved in estrogen metabolism have been described. This cross-sectional analysis
examined the relation between mammographic density and the CYP1A2*1F and COMT Val58 Met
polymorphisms among 332 breast cancer cases and 254 controls in the Hawaii component of the
Multiethnic Cohort.
Methods: Mammographic density, before diagnosis in cases, was quantified by using a validated
computer-assisted method. Blood samples were genotyped by standard PCR/RFLP methods.
Adjusted mean percent density was calculated by genotype using mixed models with the
unstructured covariance option.
Results: A positive association between the C allele in the CYP1A2*1F gene and percent density,
but not the dense area, was suggested (p = 0.11). The relation was limited to controls (p = 0.045),
postmenopausal women not using HRT (p = 0.08), and normal weight subjects (p = 0.046). We did
not observe any relation between the COMT Val58 Met polymorphism and breast density.
Conclusion: The lack of an association between the CYP1A2 genotype and the size of the dense
areas suggests an effect on the non-dense, i.e., fatty breast tissue. The discrepancies among studies
may be due to differential susceptibility; changes in enzyme activity as a result of the CYP1A2*1F
polymorphism may influence breast tissue differently depending on hormonal status. Larger studies
with the ability to look at interactions would be useful to elucidate the influence of genetic variation
in CYP1A2 and COMT on the risk of developing breast cancer.
Background
Mammographic density has been shown to be independ-
ently associated with breast cancer risk [1]. Although a
link between mammographic density and circulating
estrogen levels was only reported in one out of four
reports [2-5], postmenopausal hormone replacement
therapy (HRT) appears to increase breast density in obser-
vational and experimental studies [6,7]. In addition, asso-
ciations with genetic polymorphisms in enzymes
involved in estrogen metabolism have been explored [8-
14]. A previous study in Hawaii with predominately pre-
menopausal women showed lower mammographic den-
sities for women with the C allele in the CYP1A2*1F gene
and the Met allele in the COMT gene [10]. The CC geno-
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type for CYP1A2*1F was also significantly associated with
lower serum estradiol levels during the luteal phase [15].
The particular polymorphisms are thought to lead to
lower enzyme activity and they had been associated with
breast cancer risk in some reports [16,17]. Also, higher
CYP1A2 activity as assessed by urinary caffeine metabo-
lites was associated with higher mammographic densities
among postmenopausal women with high malondialde-
hyde (MDA) levels, an indicator of lipid peroxidation
[11]. In a case-control study nested within the Multiethnic
Cohort (MEC), postmenopausal women with at least one
C allele in the CYP1A2*1F gene had a lower risk of breast
cancer than women with the common alleles [18], but a
case-control study in Shanghai with women aged 25–64
years did not observe this association [19]. As for the Met
allele in the COMT gene, higher breast density was found
for postmenopausal HRT users in one report [8], lower
breast density in women not using HRT in another study
[9], lower breast density in pre- but not postmenopausal
women [12], higher increase in breast density in response
to estrogens during an intervention [14], and no associa-
tion among postmenopausal women [13]. To clarify the
conflicting results related to these two polymorphisms,
we linked the aforementioned case-control study [18]
with a mammographic case-control study also nested
within the MEC that had collected multiple mammo-
grams over time [20] and examined the association
between breast density and the CYP1A2*1F  and the
COMT Val58 Met polymorphisms among the overlapping
subjects.
Methods
Study population
The subjects for this analysis were originally recruited for
two separate case-control studies [18,20] nested within
the MEC study [21]. Both studies were approved by the
Human Subject Committee at the University of Hawaii.
All participants completed an informed consent form.
Controls were randomly selected from the cohort and fre-
quency matched by age and ethnicity for both studies. The
genetic polymorphism case-control study included 1,339
breast cancer cases and 1,370 controls from Hawaii and
Los Angeles [18]. Incident breast cancer cases since 1995
were identified through the rapid reporting system of the
Hawaii Tumor Registry and the Los Angeles County Can-
cer Surveillance Program. Cases and controls who agreed
to participate in the study (74% for cases and 66% for
controls) donated a blood sample. For the mammo-
graphic density case-control study [20], all incident cases
diagnosed with breast cancer in Hawaii between cohort
entry and December 2000 were eligible. Of them, 51%
agreed to be in the study and for 44% of the eligible sub-
jects a mammogram was located. The final sample size
was 607 cases and 667 controls. After linking the breast
density study with the genetic polymorphism study, 575
subjects had mammographic and genetic information
available.
Mammographic analysis
To assess breast density, the cranio-caudal views for both
sides of several mammographic examinations were
retrieved [20]. All mammograms for cases were performed
before treatment for breast cancer was initiated and only
five mammograms were taken at the time of diagnosis.
The films were scanned after removing personal identifi-
ers and quantified with a computer-assisted method by
one reader [22]. The total and the dense areas of the breast
were estimated, percent density was calculated as the ratio
of the dense to the total area of the breast, and the values
for the right and the left breast were averaged. For a subset
of mammograms read in duplicate, the intraclass correla-
tion coefficient was 0.96 for the size of the dense areas and
0.996 for the total breast area, resulting in a value of 0.974
for percent density.
Genetic analysis
DNA was extracted from white blood cells and genotyped
by PCR/RFLP methods for the COMT Val58  Met  and
CYP1A2*1F (A-154C) polymorphisms as described previ-
ously [18].
Statistical analysis
All statistical analyses were performed using SAS version 9
(Cary, NC) [23]. In order to estimate adjusted mean per-
cent density, mixed models with the unstructured covari-
ance option were applied while adjusting for age at
mammogram, BMI, case-control status, HRT use and type
(estrogen vs. combined therapy), ethnicity, parity, age at
menarche, age at first live birth, family history of breast
cancer, and menopausal status, where appropriate. A
square root transformation was applied to percent density
because the variables were not normally distributed. We
repeated some models using the log-transformed size of
the dense areas as the dependent variable. Mixed models
were used to account for the multiple density measures
per person. The availability of repeated density assess-
ments increases the statistical power of the analysis
because it decreases the intraindividual variation in den-
sity measures [24]. Age, menopausal status, and HRT use
were included as time dependent variables; all other vari-
ables were only assessed once. Genotypes were coded
according to the number of variant alleles as none, one,
and two to test for a codominant model; coding for a
recessive and a dominant model was also performed.
Adjusted mean percent densities were calculated accord-
ing to the number of variant alleles among all women and
stratified by case status, ethnicity, menopausal status, and
HRT use that were hypothesized a priori as possible mod-
ifiers. We also tested for interaction effects of genotype
with these variables. Logistic regression was used to esti-BMC Cancer 2007, 7:30 http://www.biomedcentral.com/1471-2407/7/30
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mate the risk of breast cancer related to the two genetic
polymorphisms.
Results
Due to the study design, nearly half of the 575 subjects
were breast cancer cases (Table 1). On average, three
mammograms were included per woman, but the number
of scanned films was higher for cases than for controls. At
the time of the first mammogram, the mean age was 57.1
± 9.3 years and 67% of subjects were postmenopausal. By
the time of the last mammogram, on average 4.7 years
later, 80% of women were postmenopausal. The median
time between first mammogram and breast cancer diag-
nosis was 6.6 years. Japanese women constituted the larg-
est ethnic group, followed by Caucasians and Native
Hawaiians. Approximately two-thirds of women had used
HRT at the time of at least one mammogram, but overall
44% of mammograms were performed without HRT use.
A higher proportion of controls than cases reported ERT
use, whereas combined HRT use was more common
among cases. As expected, mean percent density was sig-
nificantly higher among cases than controls; 36.7% for
cases vs. 30.6% for controls.
Adjusted percent densities were significantly higher with
an increasing number of variant alleles in the CYP1A2*1F
polymorphism among all women; the difference between
the AA and CC genotypes was 5.1% (p for trend = 0.11)
(Table 2). The respective p-values for the recessive and the
dominant model were 0.23 and 0.18 with density differ-
ences of 4.1% and 2.2% between groups (data not
shown). Although we detected no significant interaction
effects between the CYP1A2*1F polymorphism and case
status, menopausal status, and BMI (p = 0.13, 0.38, and
0.37, respectively), we noted a number of differences after
stratification by these variables. The association between
the CYP1A2*1F allele and percent density was stronger
among controls than cases. The difference between sub-
jects with AA and CC genotype was 8.9% (p = 0.045),
while there was no significant difference in breast density
by genotype among cases (p  = 0.86). Given the small
number of mammograms among premenopausal
women, the 9.6% difference between the two
homozygous groups was not significant (p  = 0.38).
Among postmenopausal women, the 9.1% difference for
mammograms taken without HRT use was close to signif-
icance (p = 0.08), whereas the difference among HRT users
was only 2.5% (p = 0.48). Similarly, the positive associa-
tion was limited to women with a BMI of less than 25 kg/
m2 (9.4%, p = 0.046), whereas percent density did not
vary by genotype among overweight and obese women.
Stratification by ethnicity showed non-significant higher
Table 1: Characteristics of the Study Population*
Characteristic Cases Controls All
Number of women 325 250 575
Ethnicity
Caucasian 112 (34.5) 74 (29.6) 186 (32.4)
Japanese 168 (51.7) 101 (40.4) 269 (46.8)
Native Hawaiian 43 (13.2) 75 (30.0) 118 (20.5)
Number of mammograms 3.4 ± 1.9 2.5 ± 1.2 3.0 ± 1.7
Age at first mammogram (years) 57.4 ± 8.9 56.8 ± 9.9 57.1 ± 9.3
Percent density at first 
mammogram (%)
36.7 ± 22.8 30.6 ± 23.3 34.0 ± 23.2
Time between first and last 
mammogram (years)
5.2 ± 3.8 4.2 ± 3.8 4.7 ± 3.8
Postmenopausal at time of first 
mammogram
233 (71.7) 153 (61.2) 386 (67.1)
Hormone replacement therapy by 
mammogram
None 472 (42.5) 290 (47.2) 762 (44.3)
Estrogen only 282 (25.5) 207 (33.7) 489 (28.4)
Estrogen plus progestin 354 (32.0) 117 (19.1) 471 (27.3)
Overweight/obese (BMI ≥ 25 kg/
m2)
121 (37.2) 113 (45.2) 234 (40.7)
Family history of breast cancer 56 (17.2) 31 (12.4) 87 (15.1)
Age at menarche younger than 13 
years
194 (59.7) 136 (54.4) 330 (57.4)
Age at first live birth older than 30 
years
29 (8.9) 26 (10.4) 55 (9.6)
Nulliparity 43 (13.2) 31 (12.4) 74 (12.9)
Parity 3+ children 72 (22.2) 53 (21.2) 125 (21.7)
* Mean ± SD are given for continuous measures, counts and percentages for other variables.BMC Cancer 2007, 7:30 http://www.biomedcentral.com/1471-2407/7/30
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Table 2: Adjusted Mean Percent Densities (%) by Genotype*
CYP1A2 N# N## Density COMT N# N## Density
All AA 863 285 27.8 Val/Val 688 229 28.6
AC 750 254 29.7 Val/Met 780 257 29.1
CC 109 36 32.9 Met/Met 254 89 29.4
P (trend)‡ -- 0.11 P (trend)‡ -- 0.70
Controls AA 315 124 22.4 Val/Val 235 95 23.6
AC 253 108 25.4 Val/Met 264 108 24.6
CC 46 18 31.3 Met/Met 115 47 25.1
P (trend)‡ -- 0.045 P (trend)‡ -- 0.61
Cases AA 548 161 31.1 Val/Val 453 134 31.4
AC 497 146 31.4 Val/Met 516 149 31.5
CC 63 18 32.0 Met/Met 139 42 30.3
P (trend)‡ -- 0.86 P (trend)‡ -- 0.84
Premenopausal AA 154 71 35.2 Val/Val 125 62 35.7
AC 129 60 36.1 Val/Met 124 55 37.8
CC 9 4 44.8 Met/Met 43 18 30.8
P (trend)‡ -- 0.38 P (trend)‡ -- 0.60
Postmenopausal AA 652 189 25.9 Val/Val 523 150 26.5
AC 566 170 27.4 Val/Met 596 174 27.0
CC 92 27 31.4 Met/Met 191 62 27.6
P (trend)‡ -- 0.14 P (trend)‡ -- 0.67
Postmenopausal AA 258 113 20.5 Val/Val 180 90 21.6
No HRT use AC 186 98 23.1 Val/Met 225 104 21.7
CC 21 11 29.6 Met/Met 60 28 24.4
P (trend)‡ -- 0.08 P (trend)‡ -- 0.57
Postmenopausal AA 228 97 29.2 Val/Val 176 81 29.3
HRT use AC 192 88 30.4 Val/Met 192 79 30.8
CC 28 14 31.7 Met/Met 80 39 29.2
P (trend)‡ -- 0.48 P (trend)‡ -- 0.88
BMI < 25 AA 504 157 34.2 Val/Val 412 135 35.4
AC 485 163 37.1 Val/Met 505 154 36.1
CC 71 21 43.6 Met/Met 143 52 37.8
P (trend)‡ - 0.046 P (trend)‡ -- 0.53
BMI >= 25 AA 359 128 19.2 Val/Val 276 94 19.0
AC 265 81 19.2 Val/Met 275 103 19.4
CC 38 15 18.6 Met/Met 111 37 18.9
P (trend)‡ - 0.92 P (trend)‡ -- 0.96
*Percent densities were computed through mixed models using square-root transformed values while adjusting for age, BMI, case status, HRT use 
& type, ethnicity, parity, age at menarche, age at first live birth, family history of breast cancer, and menopausal status. Age, HRT use, and 
menopausal status are time-dependent variables.
# N is the number of mammograms used in the analysis; ## N is the number of subjects.
‡ P-values for a trend variable assigned the gene dosage effect using mixed models.BMC Cancer 2007, 7:30 http://www.biomedcentral.com/1471-2407/7/30
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mean densities for Japanese CC carriers but no relation
among Caucasians. The mean densities for the Japanese
AA, AC, and CC carriers were 32.9%, 31.7%, and 39.4%
(p  = 0.44); the respective values for Caucasians were
26.0%, 27.9%, and 25.1% (p = 0.60).
Genotypes for COMT Val58 Met were not associated with
percent density in the entire population or in any sub-
group (Table 2). The density difference between
homozygous genotypes was less than 1% in the entire
population. The respective p-values for the recessive and
the dominant model were 0.83 and 0.70. No interaction
effect of COMT Val58 Met with case status, menopausal
status, or BMI was suggested (p = 0.71, 0.90, and 0.20,
respectively).
When we used the size of the dense areas as dependent
variable, we found no difference in mean densities by gen-
otype for CYP1A2 and COMT (p = 0.85 and 0.98).
Compared to women with the AA genotype, the risk esti-
mates for breast cancer associated with one or two C alle-
les in the CYP1A2 gene were 0.86 (95% CI = 0.60–1.23)
and 0.62 (95% CI = 0.30–1.30), respectively. For the
COMT Val58 Met polymorphism, the OR was 0.93 (95%
CI = 0.64–1.35) for one Met allele and 0.61 (95% CI =
0.37–1.02) for two Met alleles as compared to the women
with two Val alleles.
Discussion
In this analysis of longitudinal mammographic data, we
observed a weak association between percent density and
the number of C alleles in the CYP1A2*1F gene, but the
relation was limited to controls, postmenopausal women
not using HRT, and normal weight women. The fact that
the size of the dense areas was not associated with the
CYP1A2 genotype suggests that the relation may be due to
an effect on the non-dense, i.e., the fatty breast tissue. We
did not observe any relation between percent density and
the Met polymorphism in the COMT gene.
In comparison, a Canadian study reported mean percent
densities of 14% for the lowest and 31% for the highest
quartile of CYP1A2 activity (p for trend = 0.01) among
postmenopausal women not using HRT [11]. The current
findings are inconsistent with studies conducted in
Hawaii that described lower percent densities [10] and
estrogen levels [15] in premenopausal carriers of the C
allele, as well as a lower breast cancer risk among post-
menopausal women with at least one C allele for
CYP1A2*1F [18]. However, the estimated risks of 0.86
(95% CI = 0.60–1.23) for heterozygotes and 0.62 (95% CI
= 0.30–1.30) for women with the CC genotype in the cur-
rent study are very similar to the risk estimates in the
larger case-control study (OR = 1.0, 0.9 and 0.7 for the AA,
AC, and CC genotypes; p  for trend = 0.03) that also
included Latina and African-American women in Los
Angeles. The findings with regard to the COMT Val58 Met
polymorphism are also inconsistent. Studies in Hawaii
[10] and in Canada [12] suggested lower breast densities
for premenopausal carriers of the Met allele. In contrast,
one recent study found no relation among postmenopau-
sal women [13] and two reports described associations for
subgroups of postmenopausal women with the Met allele:
higher breast density for HRT users [8] and lower breast
density in women not using HRT [9].
These discrepant results for both genotypes may be due to
chance given the limited sample size, but other explana-
tions are also plausible. The small change in hormone lev-
els due to a variant allele may not be observable,
especially in light of the weak evidence for a relation
between breast density and circulating estrogen levels [2-
5]. Our observation that the relation between the CYP1A2
genotype and percent density was probably due to an
inverse association with the non-dense, i.e., the fatty tis-
sue, may offer a plausible explanation for the discrepancy
with the findings on breast cancer risk [18]. As a specula-
tion, we propose that one or two C alleles may be protec-
tive against breast cancer because the CYP1A2 genotype
might influence the amount of adipose tissue in the breast
and elsewhere. As apparent from the sex differences in
body fat distribution, steroid hormones influence fat tis-
sue, most likely through binding to sex steroid hormone
receptors that regulate the production of adipocytokines
in adipose tissue [25,26]. Therefore, differences in circu-
lating estrogen metabolite patterns due to altered enzyme
activity might modify the amount of adipose tissue in the
breast. Alternatively, the causality of the association
between genotype and amount of non-dense tissue may
be reversed. Because there is evidence that the expression
level of CYP1A2 is upregulated by estrogens [27], post-
menopausal women with more body fat and higher
endogenous estrogen production may have higher
CYP1A2 activity. The genetic polymorphism may only
affect postmenopausal women with low body fat, low
endogenous estrogens, and relatively low CYP1A2 activ-
ity, whereas the higher estrogen levels and CYP1A2 activ-
ity in women who use HRT [28], will develop breast
cancer [29], or are overweight [30] may outweigh any
changes in hormone patterns due to the CYP1A2 variant
alleles. This idea of differential susceptibility would
explain why the effects of the CYP1A2 genotype were only
apparent in certain subgroups and why our previous find-
ings in premenopausal women were so different [10,15].
In addition, a recent experimental study showed that,
among all CYP enzymes tested, CYP1A2 has the highest 2-
hydroxylation (2-OH) activity on estrone, especially at
low concentrations [31]. The positive association between
the  CYP1A2  polymorphism and breast density amongBMC Cancer 2007, 7:30 http://www.biomedcentral.com/1471-2407/7/30
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controls, women no taking HRT, and normal weight
women could be due to the higher levels of 2-OH estrone,
a metabolite with low estrogenic activity, among common
allele carriers than among women with the variant allele
resulting in greater mammographic densities among the
latter.
Strengths of this study were our prospective data from a
cohort study that minimized recall bias and the retrieval
of longitudinal mammographic data. There are a number
of serious limitations in our study. For instance, the
response rates and proportions of ethnic groups by case
status were not optimal [18,20]. Selection bias due to the
availability of mammograms may have led to a higher
proportion of women at high risk for breast cancer than in
the general population. Although we were able to show a
strong association between breast cancer diagnosis and
breast density in the mammographic density study [20],
the scanned mammograms may not have covered the crit-
ical time of a woman's life. Unmeasured confounders,
such as lipid peroxidation and intake of antioxidants
[11,32], may be partially responsible for the contradictory
findings. Although CYP1A2 activity contributes to estro-
gen metabolism, polymorphisms in other genes should
be considered by themselves and in combination. It is not
quite clear yet how much the CYP1A2*1F allele influences
actual enzyme activity. When caffeine metabolites were
measured, enzyme activity was higher among carriers of
the CYP1A2*1F  allele in one [33], but not in another
report [34]. Given the stronger association of percent den-
sity with progesterone than estrogens [3,7], polymor-
phisms related to progestin metabolism may provide
additional insights.
Conclusion
This study among a subset of MEC members suggests
higher percent densities for women carrying at least one C
allele in the CYP1A2 gene than for those with two A alleles
but no association between breast density and the Met
allele in the COMT gene. It appears that the CYP1A2 gen-
otype affects the non-dense area of the breast, but a possi-
ble mechanism of action remains to be defined. Given the
weak association between percent density and estrogens,
the alteration in enzyme activity due to the CYP1A2*1F
polymorphism may be too small to influence breast den-
sity, in particular among women who are exposed to rela-
tively high hormone levels, such as HRT users, overweight
postmenopausal women, and women who will develop
breast cancer. Until larger studies with the ability to look
at gene-gene and gene-environment interactions are com-
pleted, it will remain unclear to what extent the variant
alleles for CYP1A2 and COMT affect a woman's lifetime
risk of developing breast cancer.
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